Kornimate/medical-research-clean huggingface dataset:
a study of bomedemstat (img-7289/mk-3543) compared to best available therapy (bat) in participants with essential thrombocythemia and an inadequate response or intolerance of hydroxyurea (mk-3543-006)

Conditions: Essential Thrombocythemia

Summary: this is a study evaluating the safety and efficacy of bomedemstat (mk-3543) compared with the best available therapy (bat) in participants with essential thrombocythemia (et) who have an inadequate response to or are intolerant of hydroxyurea. the primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (dchr).


Eligibility criteria:
inclusion criteria: * has a diagnosis of et per who 2016 diagnostic criteria for myeloproliferative neoplasms (confirmed by a central pathologist) * has a centrally assessed bone marrow fibrosis score of grade 0 or grade 1, as per a modified version of the european consensus criteria for grading myelofibrosis * has a history of inadequate response to or intolerance of hydroxyurea based on modified european leukemianet (eln) criteria for hydroxyurea resistance or intolerance * has an inadequate or loss of response to their most recent prior et therapy, requiring a change of cytoreductive therapy * has a platelet count \> 450 × 10\^9/l (450k /μl) assessed up to 72 hours before first dose of study intervention * has an absolute neutrophil count (anc) ≥0.75 × 10\^9/l assessed up to 72 hours before first dose of study intervention * participants may have received up to 3 prior et-directed cytoreductive agents including hydroxyurea exclusion criteria: * known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to bomedemstat or lysine demethylase or monoamine oxidase inhibitor (lsdi or maoi) or the chosen best available therapy (including anagrelide, interferon alfa/pegylated interferon, ruxolitinib, or busulfan) that contraindicates participation * history of any illness/impairment of gi function that might interfere with drug absorption (eg, chronic diarrhea or history of gastric bypass surgical procedure), confound the study results or pose an additional risk to the individual by participation in the study * evidence at the time of screening of increased risk of bleeding * history of a malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. note: the time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder * human immunodeficiency virus (hiv)-infected participants with a history of kaposi's sarcoma and/or multicentric castleman's disease

Keywords: essential thrombocythemia et bomedemstat img-7289
invasive treatment of pain associated with pancreatic cancer on different levels of who analgesic ladder

Conditions: Pancreatic Cancer; Pain

Summary: pancreatic cancer is a difficult to treat disease, mainly due to the fact that diagnosis is made usually in the late stage of this condition. one of the treatment methods of pain accompanying this neoplasm is thoracoscopic splanchnicectomy. it has been shown that it is a safe procedure with a small percentage of complications, nevertheless it is often use as the last stage in pain management what significantly decreases its effectiveness. the aim of this study is to determinate the effect of invasive pain treatment (splanchnicectomy) in patients with advanced pancreatic cancer on subjective pain perception at rest, in movement and after meals (measured with the bpi, qlq- c30 and facit questionnaires), and suffering (measured with prism projection test), the use of painkillers during the disease and patients' overall survival. moreover the investigators want to check if early performance of splanchnicectomy (on lower steps of analgesic ladder who) is combined with better therapeutic effect of this treatment.


Eligibility criteria:
inclusion criteria: * patients diagnosed with pancreatic cancer * age over 18 years * signed informed consent to participate in the study exclusion criteria: * age under 18 years * intellectual inability to fill the questionnaires * co-occurrence of a disease in which significant chronic pain exists, which was recognized before the onset of pancreatic cancer

Keywords: pancreatic cancer pain splanchnicectomy
study of the trifunctional antibody fbta05 and donor lymphocyte infusion in b-cell lymphoma after allogeneic stem cell transplantation

Conditions: Leukemia; Stem Cell Transplantation

Summary: this study is an investigator driven, open-label, non-randomized, uncontrolled, dose escalating phase i/ii study evaluating the safety and preliminary efficacy of the trifunctional bispecific antibody fbta05 in combination with donor lymphocyte infusions (dli) for treatment of relapsed or refractory disease in cd20 positive either low- or high-grade non-hodgkin´s lymphoma after allogeneic transplantation


Eligibility criteria:
inclusion criteria: * patient´s written informed consent * ≥ 18 years of age; male and female * confirmed cll, low grade nhl or high grade nhl on standard histological or immunophenotypical criteria described in the who classification of lymphoid malignancies * cd20 positivity (if not already confirmed) * adequate haematological, liver and kidney functions * platelet count ≥25,000mm³ (=25 x 10\^9/l) * patients with active disease (relapsed/refractory) that survived at least 60 days after allogeneic transplantation * eastern cooperative oncology group (ecog) performance status \<=2 (appendix iv) * negative pregnancy test (no more than 2 days before enrolment) and adequate contraception during the study in women of child bearing potential (pre- menopausal, \<2 years post-menopausal or not surgically sterile) exclusion criteria: * any anti-cd20 and / or any other anti-t cell directed antibody treatments \< 3 months before application of fbta05 * positivity for human anti-mouse antibodies (hamas) * history of gvhd ° iii or iv, or gvhd requiring steroid therapy with more than 10 mg/day * known or suspected hypersensitivity to recombinant, murine or rat proteins * ast/sgot greater than 10 x uln (grade 3, ctcae) * bilirubin greater than 5 x uln (grade 3, ctcae) * creatinine greater than 3.5 mg/dl (grade 3, ctcae) * acute or uncontrolled chronic infections, viral infections at risk of reactivation (e.g.hcv, hbv, hiv) * unable or unwilling to comply fully with the protocol * any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study

Keywords: fbta05 cd20 cll nhl dli allogeneic transplantation cd20 positive chronic lymphocytic leukemia (cll) low and high grade non-hodgkin´s lymphoma (nhl) after allogeneic stem cell transplantation with active disease
serum lactate in acute mesenteric ischemia

Conditions: Mesenteric Ischemia

Summary: background: acute mesenteric ischemia is a vascular emergency with high mortality because of ambiguous symptomatology and a lack of early diagnostic markers. lactate dehydrogenase has been described as a mortality biomarker and bowel necrosis length too. nevertheless, the association between them has been mildly studied. our objective was to evaluate the association between serum lactate admission levels, bowel necrosis extension, and mortality. additionally, we performed a mortality characterization. materials and methods: a retrospective cross-sectional study was designed. we reviewed patients' clinical records with acute mesenteric ischemia that attended a hospital between 2012 and 2018. we compared serum lactate admission levels with bowel necrosis length and mortality. a receiver operating characteristic curve was performed on the last association. as post hoc analysis, a classification and regression tree on mortality was fitted.


Eligibility criteria:
inclusion criteria: * older than 18 years of age * required urgent laparotomy with a postoperative diagnosis of acute mesenteric ischemia * attended the private academic hospital, between 2012 and 2018 * had a registered serum lactate dehydrogenase at admission exclusion criteria: * secondary causes of ami * chronic intestinal ischemic * patient records with no description of the serum lactate dehydrogenase or extension of intestinal necrosis

Keywords: biomarker l-lactate mortality
glecaprevir/pibrentasvir for post-traumatic stress disorder

Conditions: PTSD

Summary: a double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (gle/pib), a direct acting antiviral (daa) that has been associated with posttraumatic stress disorder (ptsd) symptom improvement when prescribed for the treatment of chronic hepatitis c viral infection (hcv).

n=92 patients with posttraumatic stress disorder (ptsd) will be enrolled into a double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (gle/pib), a direct acting antiviral (daa) that has been associated with ptsd symptom improvement when prescribed for the treatment of chronic hepatitis c viral infection (hcv). the research is intended to test the efficacy of gle/pib for ptsd symptom improvement in the absence of hcv. primary aims: aim 1: determine the efficacy of gle/pib for ptsd symptom improvement. aim 2: determine the efficacy of gle/pib for functioning improvement among patients with ptsd. aim 3: assess the safety and tolerability of gle/pib treatment for patients with ptsd in the absence of hcv.

Eligibility criteria:
inclusion criteria: 1. age 19-70 years 2. weight ≥ 45 kg 3. diagnosed with ptsd as determined by the caps-5 within seven days of enrollment 4. eligible for veterans affairs healthcare 5. if person with childbearing potential, use of acceptable method of birth control (i.e., effective contraceptives, abstinence) is required. 6. able to read, understand, and sign the informed consent document. exclusion (unable to participate) criteria: 1. pregnant or lactating person 2. moderate or severe hepatic impairment (child-pugh b or c) 3. history of prior hepatic decompensation 4. current use of drugs listed as having significant drug interactions on prescribing label 5. advanced liver disease 6. current or prior hepatitis b infection 7. prior clinical use of gle/pib or hcv ns5a inhibitor and ns3/4a protease inhibitor 8. current hcv infection 9. current psychosis or mania 10. significant suicidal ideation 11. unstable medical conditions 12. current severe alcohol or substance use disorder (excluding nicotine) 13. evidence-based ptsd psychotherapy changes in the past two months 14. evidence-based ptsd medication changes in the past two months

Keywords: ptsd antiviral hepatitis c
alere i flua*b biologic test relocated in emergency service for flu diagnosis

Conditions: Flu

Summary: it appears that the heavyness of flu pathology, the diagnosis limits and the validity of it was well studied in the last years.however, the economical impact and the organisation benefit in emergency service is not yet evaluated our purpose is to study the impact of implementation of fast flu diagnosis by molecular biology available in emergency service in the economic field .


Eligibility criteria:
inclusion criteria: * respiratory symptoms * fever \>38°c * general symptoms of flu like pathology exclusion criteria: * cognitive disorders * patient with guardianship * patient already having a flu diagnosis in the last 7 days * without social protection.
proclaim: cx-072-002: study of pd-l1 probody therapeutic cx-072 in combination with other anticancer therapy in adults with solid tumors

Conditions: Solid Tumor; Unresectable or Metastatic Melanoma

Summary: to obtain evidence of antitumor effect of cx-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by response evaluation criteria in solid tumors (recist)


Eligibility criteria:
inclusion criteria: 1. at least 18 years of age 2. measurable disease as defined by recist v1.1 3. eastern cooperative oncology group (ecog) performance status of ≤1 4. agree to provide tumor tissue and blood samples for biomarker assessment exclusion criteria: 1. treatment with cytotoxic chemotherapy, biologic agents, radiation, immunotherapy, or any investigational agent within 28 days prior to the first dose of study treatment. 2. prior therapy with a chimeric antigen receptor t cell-containing regimen 3. history of active autoimmune disease(s) including but not limited to inflammatory bowel diseases, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis, systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies, type 1 insulin-dependent diabetes mellitus 4. history of myocarditis regardless of the cause 5. history of intolerance to prior checkpoint inhibitor therapy defined as the need to discontinue treatment due to an irae 6. history of any syndrome or medical condition that required treatment with systemic steroids (≥10 mg daily prednisone equivalents) or immunosuppressive medications. 7. history of severe allergic or anaphylactic reactions to human mab therapy or known hypersensitivity to any probody therapeutic

Keywords: combination ipilimumab cancer checkpoint inhibitor pd-l1 ctla-4 proclaim proclaim-cx-072 relapsed refractory
dynamic contrast enhanced computed tomography (ct) for head and neck cancer

Conditions: Head and Neck Cancer

Summary: for patients undergoing treatment for head and neck cancer, this study will use dynamic contrast-enhanced ct scans to try to determine which lymph nodes in the neck contain cancer and require surgical removal.


Eligibility criteria:
inclusion criteria: * age 18 or older * willing to provide informed consent * ecog performance status 0-2 * histologically confirmed squamous cell carcinoma (includes variants such as verrucous carcinoma, spindle cell carcinoma, carcinoma nos) of the head and neck * tumor stage: any (t1-t4) * nodal stage: * n2 or n3 (≥ 3 cm) on pre-treatment imaging for radiotherapy cohort (higher likelihood of requiring neck dissection); * n1-n3 for surgery cohort. n0 admissible for t4 tumors. * patient assessed at head and neck multidisciplinary clinic (with assessment by radiation oncologist and surgeon), with recommendation for definitive chemoradiation therapy (n=15) or surgery (n=15) exclusion criteria: * prior history of head and neck cancer within 5 years * prior head and neck radiation at any time * metastatic disease, or imaging findings suspicious for metastases * prior invasive malignant disease unless disease-free for at least 5 years or more, with the exception of non-melanoma skin cancer. * pregnant or lactating women * contraindication to dce-ct (e.g. contrast allergy)

Keywords: head and neck cancer radiation chemotherapy surgery dynamic contrast enhanced computed tomography
phase 2 study of vx-950, pegasys®, and copegus® in hepatitis c

Conditions: Chronic Hepatitis C

Summary: study the effectiveness of telaprevir (vx-950) in combination with pegylated interferon alfa 2a (peg-ifn-alfa-2a) and ribavirin (rbv) in reducing plasma hepatitis c virus (hcv) ribonucleic acid (rna) levels


Eligibility criteria:
inclusion criteria: * hepatitis c virus genotype 1 with detectable plasma hepatitis c virus rna * have been infected with hepatitis c virus for greater than (\>) 6 months * seronegative for hepatitis b surface antigen and human immunodeficiency virus 1 and 2 * must agree to use 2 methods of contraception, including 1 barrier method, during and for 24 weeks after the completion of the study (unless the subject is a female of documented non-child-bearing potential) * female subjects must have a negative pregnancy test at all visits before the first dose exclusion criteria: * received any approved or investigational drug or drug regimen for the treatment of hepatitis c * any medical contraindications to pegylated interferon alfa 2a or ribavirin therapy * any other cause of significant liver disease in addition to hepatitis c; this may include but is not limited to, hepatitis b, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, wilson's disease, nonalcoholic steatohepatitis or primary biliary cirrhosis * diagnosed or suspected hepatocellular carcinoma * histologic evidence of hepatic cirrhosis (including compensated cirrhosis) based on a liver biopsy taken within 2 years before study start * alcohol abuse or excessive use in the last 12 months * participation in any investigational drug study within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study)
ultrasound assessment of ventral hernia defects

Conditions: Ventral Incisional Hernia

Summary: quantitative radiographic imaging holds promise as a novel and innovative strategy to assess ventral hernia patients. assessing abdominal wall changes surrounding ventral hernia using shear wave velocity values measured with ultrasound will identify features of the abdominal wall that differ between healthy volunteers and subjects scheduled to have ventral hernia repair. through the use of ultrasound including shear wave velocity measurements, the abdominal wall of 25 subjects scheduled to have ventral hernia repair will be compared to those of 35 healthy volunteers. the ultrasound measurements will elucidate if ventral hernia affects abdominal wall elasticity and effect surgical outcomes.

arfi-swv ultrasound holds promise as an inexpensive, noninvasive, point-of-care diagnostic tool for pre-operatively predicting successful hernia repair. the investigators propose to develop and refine a quantitative ultrasound protocol to measure abdominal wall features suitable for predicting successful closure of the midline fascia. arfi-swv ultrasound represents a novel and intriguing modality for real time visualization and characterization of changes in the biomechanical properties of diseased musculoskeletal tissues. in this study, arfi-swv ultrasound is hypothesized to preoperatively measure the stiffness in the lateral abdominal wall as an estimation for mobility during hernia repair. preoperatively evaluating hernia severity through arfi-swv ultrasound will be performed to identify mechanical characteristics of the abdominal musculature to predict success of midline fascial re-approximation in hernia patients. the study proposes to compare ultrasound images and associated shear wave velocity measurements between 35 healthy volunteers and 25 subjects undergoing surgical repair for ventral hernia. subjects with ventral hernia will undergo imaging no earlier than two weeks prior to elective hernia repair and again postoperatively within six months following repair at a standard followup visit. statistical analysis will determine if there is a significant difference in the abdominal wall stiffness, represented by the ultrasound shear wave velocity measurements, between the healthy subjects and the subjects with ventral hernia. further analysis will determine if there is any statistically significant relationship between abdominal wall stiffness of subjects with ventral hernia and surgical outcomes.

Eligibility criteria:
inclusion criteria: * male or female between 20-70 years of age * healthy volunteer or seeking elective ventral hernia repair exclusion criteria: * pregnant women
impact of mobile text messaging on follow up rates after discharge from the pediatric emergency department

Conditions: Duty to Recontact

Summary: to compare the effectiveness of text message versus voice call as a method of contact for providing results of diagnostic tests and assuring ongoing care from the pediatric emergency department.

the investigators plan to conduct a prospective randomized controlled trial to compare two means of contacting patients and their caregivers after discharge from the emergency department in order to provide results of tests: text messaging (intervention group) vs. telephone call (standard group).

Eligibility criteria:
inclusion criteria: * patients under the age of 18 who have had diagnostic testing without finalized results prior to discharge from the emergency department exclusion criteria: * admitted patients * patients transferred to another facility * patients with critical values as results * do not have devices that can receive phone and text messages * cannot read english or spanish

Keywords: follow up text messaging
strep a fluorescent immunoassay and analyzer field study

Conditions: Strep Throat

Summary: the purpose of this study is to demonstrate the ability of the strep a fluorescent immunoassay analyzer to accurately detect a throat swab specimen for the presence or absence of strep a when compared to culture.


Eligibility criteria:
inclusion criteria: * male and female subjects three (3) years of age or older must currently be exhibiting one or more of the following symptoms characteristic of pharyngitis * extreme sore throat * redness of the posterior pharyngeal wall * difficulty swallowing * fever, \>38.7c (100f) at presentation or within past 24 hours * pharyngeal exudate * tender cervical lymphadenopathy * absence of cough or other upper respiratory symptoms exclusion criteria: * subjects currently under treatment with antibiotics are not to be included in this study. * at clinical sites requiring informed consent, unable to understand and consent to participation; for minors this includes parent or legal guardian.
relationship of metabolic syndrome and its components with thyroid nodule(s)

Conditions: Metabolic Syndrome; Thyroid Nodule

Summary: to investigate the association between metabolic syndrome (ms) and thyroid nodule(s).

to investigate the association between metabolic syndrome (ms), body mass index (bmi), hyperglycemia, dyslipidemia, hypertension and thyroid nodule(s) or thyroid functions in euthyroid subjects. screen for the risk factors that affect the incidence of thyroid nodule(s).

Eligibility criteria:
inclusion criteria: 1. people who received routain physical and laboratory examinations in the health management cenre of qianfoshan hospital from jan. 2013 to dec. 2015. 2. signed the informed consent. 3. have complete clinical data. exclusion criteria: 1. patients with previous history of thyroid disease other than thyroid nodules. 2. people with abnormal thyroid function. 3. thyroid ultrasound revealed patients with other lesions other than normal thyroid and thyroid nodules. 4. pregnant or lactating women.

Keywords: blood pressure fasting plasma glucose thyroid stimulating hormone
ewing sarcoma family of tumors (esft): a 15-year experience from a tertiary care cancer center in upper egypt

Conditions: Soft Tissue Neoplasms; Bone Neoplasms; Neoplasms

Summary: the aim of this study is to identify demographic \& disease characteristics in pediatric oncology patients diagnosed with ewing sarcoma family of tumors (esft) \& treatment outcomes in these patients.

ewing sarcoma (es) and peripheral primitive neuroectodermal tumor (pnet), both entities that currently comprise the same spectrum of neoplastic diseases known as the ewing sarcoma family of tumors (eft), were originally described as distinct clinicopathologic entities. primitive neuroectodermal tumors (pnets) first described in 1918 by stout as a malignant tumor arising from major nerve. later, in 1921, es was described as an undifferentiated tumor involving the diaphysis of long bones. it was also reported to arise in soft tissue (extraosseous es). eft is aggressive malignant small round cell tumors of bone and soft-tissue that predominantly affecting children and young adults.

Eligibility criteria:
inclusion criteria: * patients whose age less than 19 years. patients diagnosed with ewing sarcoma family of tumors (esft). exclusion criteria: * patients whose age more than 19 years. patients diagnosed with other bone \& soft tissue neoplasms.

Keywords: ewing's sarcoma (es) peripheral primitive neuroectodermal tumor (pnet)